Welcome to LookChem.com Sign In|Join Free

Hubei Vanz Pharm Co.,Ltd

Diamond Supplier Enterprise Certification

Diamond
Supplier
5th
years
Home>>Products>>cas 698387-09-6 99% Neratinib powder

Product Certification&
Enterprise Certification

More Detail

Hubei Vanz Pharm Co.,Ltd

Country: China (Mainland)

Business Type:Trading Company

Ms.Chelsea gao

Tel: 86-27-84492310

Ms.Bella Li

Tel: 008618986076206

Ms.Chelsea Gao

Tel: +86 27 84492310

Ms.Wendy

Tel: WhatsApp +8615927784577

Ms.Mirriam

Tel: +8618071739296

Mobile:

Tel: 86-27-84492310

Fax: 86-27-84402310

URL: http://www.vanzpharm.com/en/index.html

Province/state: Hubei

City: JIAYU

Street: FANHU INDUSTRY PARK

MaxCard:


    x
  • Ms.Bella Li
  • Ms.Chelsea Gao
Contact Suppliers

cas 698387-09-6 99% Neratinib powder

CAS NO.698387-09-6

  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T,MoneyGram
Contact Supplier

Product Details

Keywords

  • Neratinib
  • Neratinib powder
  • 99% Neratinib

Quick Details

  • ProName: cas 698387-09-6 99% Neratinib powder
  • CasNo: 698387-09-6
  • Molecular Formula: C30H29ClN6O3
  • Appearance: white
  • Application: Anti cancer
  • DeliveryTime: 7-10 days
  • PackAge: drum
  • Port: Shanghai/Wuhan
  • ProductionCapacity: 1000 Kilogram/Day
  • Purity: 99
  • Storage: room
  • LimitNum: 1 Kilogram

Superiority


cas 698387-09-6 99% Neratinib  powder

Product Name: Neratinib
CAS: 698387-09-6
MF: C30H29ClN6O3
MW: 557.04
EINECS: 811-237-1

 

Details

What is Neratinib

The receptor tyrosine kinase HER2 (ErbB2) is a key component of epidermal growth factor receptor complexes that are known to have central roles in cell proliferation and cancer. Neratinib is an orally active, irreversible inhibitor of the HER2 kinase (IC50 = 59 nM). It also potently inhibits several mutants of HER2 and shows 10-fold or greater selectivity over a wide variety of other kinases. As an irreversible inhibitor, neratinib may circumvent acquired resistance developed against reversible inhibitors, including gefitinib .


Neratinib Function

Neratinib has been evaluated in clinical trials against cancers characterized by HER2 overexpression or HER2 activating mutations. Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM, respectively. irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Antitumor agent